Crossmark Global Holdings Inc. Boosts Stock Holdings in Glaukos Co. (NYSE:GKOS)

Crossmark Global Holdings Inc. increased its stake in Glaukos Co. (NYSE:GKOS) by 15.8% in the 3rd quarter, Holdings Channel.com reports. The fund owned 4,051 shares of the medical instruments supplier’s stock after acquiring an additional 554 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Glaukos were worth $527,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. purchased a new stake in Glaukos in the 2nd quarter worth $6,832,000. Natixis purchased a new stake in Glaukos in the 1st quarter worth $614,000. Vanguard Group Inc. boosted its stake in Glaukos by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock worth $500,576,000 after purchasing an additional 72,159 shares during the last quarter. UniSuper Management Pty Ltd acquired a new stake in Glaukos during the 1st quarter worth $913,000. Finally, Seven Eight Capital LP acquired a new stake in Glaukos during the 2nd quarter worth $1,940,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Needham & Company LLC lifted their target price on shares of Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Truist Financial lifted their target price on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Piper Sandler set a $140.00 target price on shares of Glaukos in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $134.55.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total transaction of $646,800.00. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $13,216,581.84. This represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,275 shares of company stock valued at $1,354,967 over the last 90 days. 6.40% of the stock is owned by company insiders.

Glaukos Trading Down 0.1 %

Shares of GKOS stock opened at $138.44 on Friday. The company’s 50-day moving average price is $130.92 and its 200-day moving average price is $122.40. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a market cap of $7.63 billion, a price-to-earnings ratio of -45.84 and a beta of 1.02. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $145.84.

Glaukos (NYSE:GKOS) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Glaukos’s revenue was up 23.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.50) earnings per share. As a group, equities analysts predict that Glaukos Co. will post -1.96 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.